Immunological mechanisms of severe respiratory syncytial virus bronchiolitis

Intensive Care Medicine

Volumn 28, Issue 5, 2002, Pages 616-621

  Bont, Louis ^a   Kimpen, Jan L ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Artificial respiration; Immunity; Pathogenesis; Respiratory syncytial virus; Review

Indexed keywords

EOSINOPHIL CATIONIC PROTEIN; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 4; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ANTIBODY TITER; ARTIFICIAL VENTILATION; BRONCHIOLITIS; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; DISEASE SEVERITY; EOSINOPHIL; HUMAN; HUMORAL IMMUNITY; IMMATURITY; IMMUNE RESPONSE; INFANCY; LYMPHOCYTE COUNT; MORBIDITY; NEUTROPHIL; NONHUMAN; PATHOGENESIS; PREMATURITY; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; RISK FACTOR; T LYMPHOCYTE;

BRONCHIOLITIS, VIRAL; HUMANS; INFANT; INFANT, NEWBORN; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN;

EID: 0036260116     PISSN: 03424642     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00134-002-1256-z     Document Type: Review

References (73)

1. Respiratory syncytial virus
2. Severe respiratory syncytial virus disease in Alaska native children
3. Bronchiolitis-associated hospitalizations among US children, 1980-1996
4. Respiratory syncytial virus infection in pediatric patients
5. Management of respiratory failure in infants with acute viral bronchiolitis
6. Clinical observations on mechanical ventilation for respiratory failure in bronchiolitis
7. Risk factors for mechanical ventilation in respiratory syncytial virus infection
8. Neonatal respiratory syncytial virus infection
9. Respiratory syncytial virus infection in infants with congenital heart disease
10. Testing models predicting severity of respiratory syncytial virus infections on the PICNIC RSV database
11. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier
12. Pediatric Investigators Collaborative Network on infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lower respiratory tract infection
13. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis
14. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants
15. Prophylaxis against respiratory syncytial virus in premature infants
16. Diminished lung function as a predisposing factor for wheezing respiratory illness in infants
17. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13
18. Role of respiratory viruses in childhood mortality
19. Pathological changes in virus infections of the lower respiratory tract in children
20. Demonstration of respiratory syncytial virus in an autopsy series
21. Nasal quantity of respiratory syncytial virus correlates with disease severity in hospitalized infants
22. Respiratory syncytial virus infections in infants: Quantitation and duration of shedding
23. Severity of respiratory syncytial virus disease related to type and genotype of virus and to cytokine values in nasopharyngeal secretions
24. Relationship between clinical severity of respiratory syncytial virus infection and subtype
25. Clinical severity of respiratory syncytial virus group A and B infection in Sydney, Australia
26. Clinical characteristics of respiratory syncytial virus (RSV) subgroup infections in Japan
27. Antigenic characterization of respiratory syncytial virus strains with monoclonal antibodies
28. Influence of immunological factors in respiratory syncytial virus disease
29. The appearance of cell-bound IgE in respiratory-tract epithelium after respiratory-syncytial-virus infection
30. The development of respiratory syncytial virus-specific IgE and the release of histamine in nasopharyngeal secretions after infection
31. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children
32. T cell subset analysis in peripheral blood of children with RSV bronchiolitis
33. Reduced interferon-gamma expression in peripheral blood mononuclear cells of infants with severe respiratory syncytial virus disease
34. Association of peripheral blood cytokine responses with disease severity in respiratory syncytial virus bronchiolitis
35. Local interferon-gamma levels during respiratory syncytial virus lower respiratory tract infection are associated with disease severity
36. Monocyte interleukin-12 production is inversely related to duration of respiratory failure in respiratory syncytial virus bronchiolitis
37. IL-12 as an adjuvant for cell mediated immunity
38. Cellular immunity is activated and a Th2-response is associated with early wheezing in infants after bronchiolitis
39. Respiratory syncytial virus infection in infants is associated with predominant Th-2-like response
40. Monocyte IL-10 production during respiratory syncytial virus bronchiolitis is associated with recurrent wheezing in a one-year follow-up study
41. Analysis of cells obtained by bronchial lavage of infants with acute respiratory syncytial virus infection
42. Leucocyte populations in respiratory syncytial virus- induced bronchiolitis
43. IL-8 and neutrophil elastase levels in the respiratory tract of infants with RSV bronchiolitis
44. Eosinophil degranulation in the respiratory tract during naturally acquired respiratory syncytial virus infection
45. Eosinophil cationic protein in nasopharyngeal secretions and serum of infants infected with respiratory syncytial virus
46. Prophylaxis against respiratory syncytial virus (RSV) in premature infants
47. T-cell function in newborn mice and humans
48. Regulation of immune functions in the fetus and newborn
49. Immunity in the neonate
50. Immunological basis for increased susceptibility of the neonate to infection
51. Impaired cellular immunity to cytomegalovirus in congenitally infected children and their mothers
52. Immunobiology of childhood tuberculosis: A window on the ontogeny of cellular immunity
53. Diminished interferon-gamma and lymphocyte proliferation in neonatal and postpartum primary herpes simplex virus infection
54. Herpes simplex virus-stimulated gamma-interferon production by newborn mononuclear cells
55. Mechanisms of innate resistance to Toxoplasma gondii infection
56. Immunoglobulin and cytokine production by neonatal lymphocytes
57. Fetal natural killer cell function is suppressed
58. Postnatal maturation of immune competence during infancy and childhood
59. Developmental shift in the patterns of interleukin production in early post-natal life
60. Respiratory syncytial virus-induced cytokine production by a human bronchial epithelial cell line
61. Respiratory syncytial virus and human bronchial epithelium
62. Interleukin-1 alpha mediates the enhanced expression of intercellular adhesion molecule-1 in pulmonary epithelial cells infected with respiratory syncytial virus
63. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine
64. Immunity and immunopathology to respiratory syncytial virus
65. Pathogenesis of respiratory syncytial virus vaccine-augmented pathology
66. The relationship of acute bronchiolitis to bronchial asthma - A 4 to 14 year follow-up
67. Community study of role of viral in fections in exacerbations of asthma in 9-11 year old children
68. The relationship between upper respiratory infections and hospital admissions for asthma: A time-trend analysis
69. Wheezing, asthma and pulmonary dysfunction 10 years after infection with respiratory syncytial virus infection in infancy
70. Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice
71. Primary respiratory syncytial virus infection in mice
72. Respiratory failure and mechanical ventilation in severe bronchiolitis